Newer hypomethylating agents like azacitidine offer hope for older patients with acute myeloid leukaemia, according to Professor Hervé Dombret from the University Hospital Saint-Louis in Paris. “The current approach subdivides older patients into those capable of tolerating intensive chemotherapy, those who may only tolerate low-intensity therapy such as low-dose cytarabine or hypomethylating agents like azacitidine, ...
New options for older patients with AML
By Tony James
20 Oct 2015